SG11202103045SA - Split interleukin mimetics and their use - Google Patents

Split interleukin mimetics and their use

Info

Publication number
SG11202103045SA
SG11202103045SA SG11202103045SA SG11202103045SA SG11202103045SA SG 11202103045S A SG11202103045S A SG 11202103045SA SG 11202103045S A SG11202103045S A SG 11202103045SA SG 11202103045S A SG11202103045S A SG 11202103045SA SG 11202103045S A SG11202103045S A SG 11202103045SA
Authority
SG
Singapore
Prior art keywords
mimetics
interleukin
split
split interleukin
interleukin mimetics
Prior art date
Application number
SG11202103045SA
Other languages
English (en)
Inventor
Rubio Alfredo Quijano
Manzano Daniel Silva
David Baker
Umut Ulge
Marc Lajoie
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Publication of SG11202103045SA publication Critical patent/SG11202103045SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5437—IL-13
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11202103045SA 2018-11-20 2019-11-19 Split interleukin mimetics and their use SG11202103045SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862770152P 2018-11-20 2018-11-20
PCT/US2019/062198 WO2020106708A1 (en) 2018-11-20 2019-11-19 Split interleukin mimetics and their use

Publications (1)

Publication Number Publication Date
SG11202103045SA true SG11202103045SA (en) 2021-04-29

Family

ID=69500815

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202103045SA SG11202103045SA (en) 2018-11-20 2019-11-19 Split interleukin mimetics and their use

Country Status (13)

Country Link
US (2) US12234572B2 (https=)
EP (1) EP3883956A1 (https=)
JP (2) JP2022511390A (https=)
KR (1) KR20210094531A (https=)
CN (2) CN112912388A (https=)
AU (1) AU2019384523B2 (https=)
BR (1) BR112021008985A2 (https=)
CA (1) CA3119472A1 (https=)
EA (1) EA202190593A1 (https=)
IL (1) IL283217A (https=)
MX (1) MX2021005593A (https=)
SG (1) SG11202103045SA (https=)
WO (1) WO2020106708A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
EP3810640A1 (en) * 2018-06-25 2021-04-28 University of Washington De novo design of potent and selective interleukin mimetics
EP3818083A2 (en) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
EP3883956A1 (en) 2018-11-20 2021-09-29 University of Washington Split interleukin mimetics and their use
JP7710373B2 (ja) 2019-02-21 2025-07-18 マレンゴ・セラピューティクス，インコーポレーテッド Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
CN116234829A (zh) 2020-01-03 2023-06-06 马伦戈治疗公司 抗tcr抗体分子及其用途
EP4288548A4 (en) * 2021-02-05 2025-01-15 Dharmacon, Inc. FUSION PROTEINS FOR CRISPR-BASED TRANSCRIPTION REPRESSION
WO2023044318A2 (en) * 2021-09-15 2023-03-23 Neoleukin Therapeutics, Inc. Interleukin-2 receptor βeta (il-2rβ) binding polypeptides
CN118715024A (zh) * 2022-01-24 2024-09-27 诺夫免疫股份有限公司 用于细胞因子信号传导通路的选择性激活的组合物和方法
IL322524A (en) 2023-03-07 2025-10-01 Chugai Pharmaceutical Co Ltd Conditional receptor signaling via scaffolding protein
EP4722235A1 (en) * 2023-05-24 2026-04-08 Nantong Yichen Biopharma. Co. Ltd. Polypeptide, and conjugate and use thereof
TW202519542A (zh) * 2023-07-13 2025-05-16 美商奧特佩斯生化股份有限公司 經設計之細胞激素組合物及使用方法
WO2025212606A1 (en) * 2024-04-01 2025-10-09 Bio-Techne Corporation Synthetic il-2 polypeptides and conjugates, compositions, and uses thereof
WO2026039791A1 (en) * 2024-08-16 2026-02-19 Regeneron Pharmaceuticals, Inc. Tumor-targeted split il2 receptor agonists
WO2026078029A1 (en) * 2024-10-10 2026-04-16 F. Hoffmann-La Roche Ag Splitted interleukin-2 prodrugs and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1015080A (en) 1908-04-17 1912-01-16 George I Rockwood Apparatus for operating alarms or other devices.
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
US6955807B1 (en) 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
US6168785B1 (en) 1998-07-16 2001-01-02 Institut Pasteur Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents
GB0019638D0 (en) * 2000-08-09 2000-09-27 European Molecular Biology Lab Embl Peptide mimetics
MXPA03011158A (es) 2001-06-07 2004-02-27 Wyeth Corp Estructura de solucion de il - 13 y sus usos.
CN1930300A (zh) * 2004-03-05 2007-03-14 希龙公司 预测患者治疗药物耐受性的体外试验系统
US20110020269A1 (en) 2007-05-08 2011-01-27 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for modifying t cell immune responses and inflammation
US9676871B2 (en) 2010-11-05 2017-06-13 Pfizer Inc. Engineered polypeptide conjugates and methods for making thereof using transglutaminase
US9428567B2 (en) 2010-12-22 2016-08-30 The Board Of Trustees Of The Leland Stanford Junior University Antagonists of interleukin-2 receptor
US9844582B2 (en) 2012-05-22 2017-12-19 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
WO2015164815A1 (en) 2014-04-24 2015-10-29 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
US9777070B2 (en) 2014-04-30 2017-10-03 Pfizer Inc Anti-PTK7 antibody-drug conjugates
WO2016025385A1 (en) 2014-08-11 2016-02-18 Delinia, Inc. Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
AR105616A1 (es) 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
WO2018153865A1 (en) 2017-02-24 2018-08-30 Philogen S.P.A. Immunoconjugates with optimized linkers and orientation
ES2894731T3 (es) 2017-03-15 2022-02-15 Silverback Therapeutics Inc Compuestos de benzazepina, conjugados y usos de los mismos
EP3810640A1 (en) 2018-06-25 2021-04-28 University of Washington De novo design of potent and selective interleukin mimetics
EP3883956A1 (en) 2018-11-20 2021-09-29 University of Washington Split interleukin mimetics and their use
EP3883585A4 (en) 2018-11-20 2022-12-14 Innovative Cellular Therapeutics Holdings, Ltd. MODIFIED CELL EXPRESSING THERAPEUTIC AND USES THEREOF
JP2022553370A (ja) 2019-10-25 2022-12-22 ネオルーキン セラピューティクス，インコーポレイティド Ｉｌ－２受容体作動薬の投与方法
US20230331858A1 (en) 2019-12-24 2023-10-19 Neoleukin Therapeutics, Inc. Combination therapy using an il-2 receptor agonist and an immune checkpoint inhibitor
CN111040981A (zh) 2019-12-26 2020-04-21 南昌大学 表达重组IL-2的重组大肠杆菌Nissle 1917及其功能验证方法
EP4121449A2 (en) 2020-03-16 2023-01-25 Neoleukin Therapeutics, Inc. Interleukin-2 receptor beta (il-2rb) binding polypeptides

Also Published As

Publication number Publication date
US12234572B2 (en) 2025-02-25
IL283217A (en) 2021-06-30
CN120040576A (zh) 2025-05-27
CN112912388A (zh) 2021-06-04
US20220017588A1 (en) 2022-01-20
BR112021008985A2 (pt) 2021-10-26
AU2019384523A1 (en) 2021-04-22
WO2020106708A1 (en) 2020-05-28
US20250179690A1 (en) 2025-06-05
EP3883956A1 (en) 2021-09-29
AU2019384523B2 (en) 2025-08-28
CA3119472A1 (en) 2020-05-28
MX2021005593A (es) 2021-08-11
JP2022511390A (ja) 2022-01-31
KR20210094531A (ko) 2021-07-29
EA202190593A1 (ru) 2021-11-18
JP2025013348A (ja) 2025-01-24

Similar Documents

Publication Publication Date Title
SG11202103045SA (en) Split interleukin mimetics and their use
IL294052B2 (en) Fluoroalkyl oxadiazoles and their uses
ZA202006904B (en) Anti-il-4r antibody and use thereof
IL279458A (en) Neoantigens and their uses
GB2576389B (en) Refrigerant composition and use thereof
SG11202100746WA (en) Anti-tigit antibody and use thereof
IL274844A (en) IL-2 mutants and their uses
ZA201900772B (en) Heterodimeric fc-fused cytokine and pharmaceutical composition comprising the same
IL293980B1 (en) New compounds and their use
IL282707A (en) Anti-tim-3 antibodies and their use
IL277749A (en) Palladianolide compounds and their use
IL282708A (en) Anti-tim-3 antibodies and their use
SG11202010601VA (en) Antibody variant combinations and uses thereof
GB2600592B (en) Polypeptide and use thereof
IL287503A (en) Thio-semicarbazide compounds and their use
GB201819200D0 (en) Polypeptide and uses thereof
IL280644A (en) Magnesium serine compound and its use
SG11202102182VA (en) Desiccant composition and use thereof
GB201802122D0 (en) Product and use
IL276984A (en) Insecticides and their use
IL278919A (en) Combinations comprising tropifexor and cenicriviroc
IL280369A (en) Myokines and their uses
GB201906914D0 (en) Substituted naphtahlene diimdes and their use
HK40064147A (en) Split interleukin mimetics and their use
GB201901413D0 (en) Compositions and their use